Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024 12:15 ET
|
Regeneron Pharmaceuticals, Inc.
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and...
Virbac : Public release of the Half-Year Financial Report at 30 June 2024.
September 13, 2024 12:15 ET
|
Virbac
Public release of the Half-Year Financial Report at 30 June 2024. The Group released and filed its 2024 half-year financial report with the French “Autorité des marchés financiers”. The document is...
Virbac : Half-yearly financial report 2024
September 13, 2024 12:15 ET
|
Virbac
Please find attached 2024 Half-yearly financial report of Virbac
Attachment
Half-Yearly Financial Report_2024 for publication
...
BC’s Rental Protection Fund Announces Acquisition of 147 more affordable rental units across the Lower Mainland
September 13, 2024 12:15 ET
|
Rental Protection Fund
VANCOUVER, British Columbia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Today, the Rental Protection Fund (the Fund) announces three acquisitions in communities throughout the Lower Mainland. In Vancouver,...
Digital Health Market Size on Track to Reach USD 1.1 Trillion by 2031, Driven by 13.1% CAGR Growth| Exclusive Research Report by Transparency Market Research Inc.
September 13, 2024 12:13 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 13, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global digital health...
Le traitement prophylactique par dexaméthasone réduit les réactions liées à la perfusion chez les patients atteints d'un cancer du poumon non à petites cellules avancé muté EGFR et traités par RYBREVANT® ▼ (amivantamab) par voie intraveineu
September 13, 2024 12:09 ET
|
Janssen Cilag International NV
La prémédication à une dose de 8 mg à entraîné un taux de réaction lié à la perfusion de 22,5 pour cent avec l'amivantamab par voie intraveineuse, soit trois fois moins que le taux de 67,4 pour cent...
Faruqi & Faruqi Reminds STMicroelectronics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 22, 2024 - STM
September 13, 2024 12:06 ET
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In STMicroelectronics To Contact Him Directly To Discuss Their...
DEADLINE ALERT for STM, DAVA, and MEI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
September 13, 2024 12:06 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
September 13, 2024 12:05 ET
|
BioNexus Gene Lab Corp.
KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is...
Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun
September 13, 2024 12:03 ET
|
Kaldalón hf.
Í viku 37 keypti Kaldalón hf. 2.192.268 eigin hluti að kaupvirði kr. 40.830.991 skv. sundurliðun hér á eftir; VikaDagsetningTímiMagnVerðKaupverðVika 379.9.202410:111.096.13418,820.607.319Vika...
- September 13, 2024 12:06 ET Faruqi & Faruqi Reminds STMicroelectronics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 22, 2024 - STM
- September 13, 2024 12:03 ET Faruqi & Faruqi Reminds Super Micro Computer Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 29, 2024 - SMCI